Essential Thrombocythemia Incidentally Discovered in 5-year-old Patient: A Case Report

Momen A. Zaid^1, , Oadi N. Shrateh², Mariam Thalji² and Yara Assaf²

¹Research and Clinical Teaching Assistant, Faculty of Medicine, Al-Quds University, Jerusalem, Palestine

²Faculty of medicine, Al-Quds University, Jerusalem, Palestine

Cite this paper

Momen A. Zaid, Oadi N. Shrateh, Mariam Thalji and Yara Assaf. Essential Thrombocythemia Incidentally Discovered in 5-year-old Patient: A Case Report. American Journal of Medical Case Reports. 2023; 11(3):55-59. doi: 10.12691/AJMCR-11-3-4

Abstract

Essential thrombocythemia (ET) is considered a classic” BCR-ABL1-negative chronic myeloproliferative condition (MPD) that’s characterized by thrombocytosis, bleeding, and/or thrombosis. It usually affects the megakaryocytic cell lineage. While the disease is most commonly observed in people between the ages of 50 and 60, ET is an extremely rare myeloproliferative disorder in the pediatric age group. In children under the age of 14, the annual incidence of ET is estimated to be 1 per 10 million, approximately 60 times lower than older ages. Most ET patients, especially children are asymptomatic and discovered incidentally while doing investigations for other reasons. Herein, we introduce a very rare case of essential thrombocythemia in a 5-year-old male patient that was detected incidentally following receiving the influenza vaccine. The patient had a persistent elevated platelet count over 450x109 /L. Bone marrow showed markedly increased megakaryocyte number. Genetic testing and bcr/abl rearrangement were unremarkable. The patient showed no symptoms during the period of follow-up.

Keywords

essential thrombocythemia

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Aladily, T.N., et al., Essential thrombocythemia in a two-year-old child, responsive to hydroxyurea but not aspirin. Oman medical journal, 2017. 32(3): p. 243.
[2]	Vafaie, M., et al., Asymtomatic essential thrombocythemia in a child: a rare case report. International Journal of Hematology-Oncology and Stem Cell Research, 2013. 7(2): p. 35.
[3]	Epstein, E. and A. Goedel, Hemorrhagic thrombocythemia with a cascular, sclerotic spleen. Virchows Arch, 1934. 293: p. 233-248.
[4]	Swerdlow, S.H., et al., WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. 2008: International agency for research on cancer Lyon.
[5]	Fu, R., L. Zhang, and R. Yang, Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. British journal of haematology, 2013. 163(3): p. 295-302.
[6]	Kucine, N., Myeloproliferative neoplasms in children, adolescents, and young adults. Current hematologic malignancy reports, 2020. 15(2): p. 141-148.
[7]	Michiels, J.J., et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. in Seminars in thrombosis and hemostasis. 2006. Copyright© 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ….
[8]	Putti, M.C., I. Bertozzi, and M.L. Randi, Essential Thrombocythemia in Children and Adolescents. Cancers, 2021. 13(23): p. 6147.
[9]	Arber, D.A., et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, The Journal of the American Society of Hematology, 2016. 127(20): p. 2391-2405.
[10]	Tefferi, A. and A. Pardanani, Essential Thrombocythemia. N Engl J Med, 2019. 381(22): p. 2135-2144.
[11]	Cervantes, F., Management of essential thrombocythemia. Hematology 2010, the American Society of Hematology Education Program Book, 2011. 2011(1): p. 215-221.
[12]	Cervantes, F., Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program, 2011. 2011: p. 215-21.
[13]	Barbui, T., et al., The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev, 2016. 30(6): p. 453-459.
[14]	Tefferi, A., A.M. Vannucchi, and T. Barbui, Essential thrombocythemia treatment algorithm 2018. Blood Cancer J, 2018. 8(1): p. 2.
[15]	Ashorobi, D. and P. Gohari, Essential Thrombocytosis, in StatPearls. 2022: Treasure Island (FL).
[16]	Cooper TM, H., Smith FO, In Pizzo PA, Poplack DG, Principle and practice of pediatric oncology. 2011, Philadelphia: Lippincott Williams &Wilkins: Lippincott Williams &Wilkins.
[17]	Kucine, N., et al., Primary thrombocytosis in children. Haematologica, 2014. 99(4): p. 620-8.
[18]	Dame, C. and A.H. Sutor, Primary and secondary thrombocytosis in childhood. Br J Haematol, 2005. 129(2): p. 165-77.
[19]	Mehta, J., et al., Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma, 2014. 55(3): p. 595-600.
[20]	Sungaran, R., B. Markovic, and B.H. Chong, Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood, 1997. 89(1): p. 101-7.
[21]	Zeigler, F.C., et al., In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood, 1994. 84(12): p. 4045-52.
[22]	Mehta, J., et al., Epidemiology of myeloproliferative neoplasms in the United States. Leukemia & lymphoma, 2014. 55(3): p. 595-600.
[23]	Qian, S., et al., Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood, The Journal of the American Society of Hematology, 1998. 92(6): p. 2189-2191.
[24]	Vannucchi, A.M. and P. Guglielmelli, What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? Hematology Am Soc Hematol Educ Program, 2017. 2017(1): p. 480-488.
[25]	Tefferi, A. and A. Pardanani, Essential thrombocythemia. New England Journal of Medicine, 2019. 381(22): p. 2135-2144.
[26]	Tefferi, A. and A. Pardanani, Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol, 2015. 1(1): p. 97-105.
[27]	Vainchenker, W. and R. Kralovics, Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 2017. 129(6): p. 667-679.
[28]	Meier, B. and J.H. Burton, Myeloproliferative Disorders. Hematol Oncol Clin North Am, 2017. 31(6): p. 1029-1044.
[29]	Barbui, T., M.C. Finazzi, and G. Finazzi, Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev, 2012. 26(5): p. 205-11.
[30]	Barbui, T., et al., Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J, 2015. 5: p. e369.
[31]	Dror, Y. and V.S. Blanchette, Essential thrombocythaemia in children. Br J Haematol, 1999. 107(4): p. 691-8.
[32]	Matsubara, K., et al., Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematol, 2004. 111(3): p. 132-7.
[33]	Vora, A.J. and J.S. Lilleyman, Secondary thrombocytosis. Arch Dis Child, 1993. 68(1): p. 88-90.
[34]	Wolber, E.M., et al., Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb Haemost, 2001. 86(6): p. 1421-4.
[35]	Ishiguro, A., et al., Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol, 2002. 116(3): p. 612-8.
[36]	Bilic, E. and E. Bilic, Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia. J Pediatr Hematol Oncol, 2003. 25(8): p. 675-6.
[37]	Geddis, A.E. and K. Kaushansky, Cross-reactivity between erythropoietin and thrombopoietin at the level of Mpl does not account for the thrombocytosis seen in iron deficiency. J Pediatr Hematol Oncol, 2003. 25(11): p. 919-20; author reply 920.
[38]	Matsubara, K., et al., Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta haematologica, 2004. 111(3): p. 132-137.
[39]	Ghilardi, N., et al., Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol, 1999. 107(2): p. 310-6.
[40]	Wiestner, A., et al., An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet, 1998. 18(1): p. 49-52.
[41]	Bleeker, J.S. and W.J. Hogan, Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis, 2011. 2011: p. 536062.
[42]	Barbui, T., How to manage children and young adults with myeloproliferative neoplasms. Leukemia, 2012. 26(7): p. 1452-7.
[43]	Besses, C. and A. Alvarez-Larran, How to Treat Essential Thrombocythemia and Polycythemia Vera. Clin Lymphoma Myeloma Leuk, 2016. 16 Suppl: p. S114-23.
[44]	Carobbio, A., et al., Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood, 2011. 117(22): p. 5857-9.
[45]	Tefferi, A., Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol, 2012. 87(3): p. 285-93.
[46]	Posthuma, H.L., et al., Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood, 2010. 116(17): p. 3375-6.
[47]	Aruch, D. and J. Mascarenhas, Contemporary approach to essential thrombocythemia and polycythemia vera. Curr Opin Hematol, 2016. 23(2): p. 150-60.
[48]	Barbui, T., et al., Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol, 2011. 29(6): p. 761-70.
[49]	Cerquozzi, S. and A. Tefferi, Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J, 2015. 5: p. e366.
[50]	Passamonti, F., et al., Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med, 2004. 117(10): p. 755-61.